Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells $104,463.04 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTXGet Free Report) CFO Christopher R. Cline sold 5,192 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $104,463.04. Following the completion of the sale, the chief financial officer now owns 90,038 shares of the company’s stock, valued at approximately $1,811,564.56. This trade represents a 5.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Travere Therapeutics Stock Up 4.4 %

Shares of TVTX stock traded up $0.88 on Tuesday, hitting $21.10. The company’s stock had a trading volume of 987,233 shares, compared to its average volume of 1,250,242. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -4.64 and a beta of 0.72. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $21.56. The firm’s fifty day moving average price is $18.69 and its 200-day moving average price is $15.47.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in Travere Therapeutics in the 4th quarter worth approximately $53,000. CWM LLC lifted its stake in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares during the last quarter. Quarry LP acquired a new position in Travere Therapeutics in the 3rd quarter valued at $105,000. Sei Investments Co. bought a new position in Travere Therapeutics in the 2nd quarter worth $117,000. Finally, Diversified Trust Co bought a new position in Travere Therapeutics in the 3rd quarter worth $161,000.

Analyst Ratings Changes

A number of research firms have recently issued reports on TVTX. Bank of America increased their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Piper Sandler raised their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Wedbush upped their target price on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. HC Wainwright raised their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Finally, Barclays upped their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.00.

View Our Latest Report on TVTX

Travere Therapeutics Company Profile

(Get Free Report)

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

See Also

Insider Buying and Selling by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.